Vir Biotechnology, Inc. is a San Francisco-based biotechnology company that specializes in harnessing deep immunology expertise to develop transformative medicines for infectious diseases, viral-associated diseases, and immune-mediated diseases. With a proven track record in monoclonal antibody (mAb) development and artificial intelligence-led mAb optimization, Vir has built a robust pipeline of ongoing trials and late-stage programs, including chronic hepatitis delta and chronic hepatitis B, with the aim of addressing unmet patient needs worldwide.
Powered by their ability to leverage the human immune system and engineer human-derived antibodies, Vir's impactful medicines are a result of their deep knowledge of immunology and understanding of the intricate interplay between viruses and the human immune system. With an experienced leadership team and Board of Directors, Vir is committed to progressing product candidates from early-stage research through clinical development, regulatory approval, and commercialization, making a significant impact in the field of immunology and infectious diseases.
Generated from the website